Generic drug makers are applauding the latest change to the health care bill — eliminating the ban on patent settlements.

The measure, which was backed by the Federal Trade Commission, would in most cases have barred so-called “pay for delay” settlements of patent cases brought by generic companies against brand-name drug makers. In such cases, the brand-name maker pays the generic company to delay the market entry of a lower-cost generic drug alternative.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]